NO20073859L - Pyrrolopyrazoler, potente kinaseinhibitorer - Google Patents

Pyrrolopyrazoler, potente kinaseinhibitorer

Info

Publication number
NO20073859L
NO20073859L NO20073859A NO20073859A NO20073859L NO 20073859 L NO20073859 L NO 20073859L NO 20073859 A NO20073859 A NO 20073859A NO 20073859 A NO20073859 A NO 20073859A NO 20073859 L NO20073859 L NO 20073859L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
pyrrolopyrazoles
potent kinase
compounds
potent
Prior art date
Application number
NO20073859A
Other languages
English (en)
Norwegian (no)
Inventor
Yufeng Hong
Djamal Bouzida
Liming Dong
Chuangxing Guo
Haitao Li
Joseph Timothy Marakovits
Anle Yang
Junhu Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20073859L publication Critical patent/NO20073859L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20073859A 2005-01-10 2007-07-23 Pyrrolopyrazoler, potente kinaseinhibitorer NO20073859L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64290005P 2005-01-10 2005-01-10
US73377005P 2005-11-04 2005-11-04
PCT/IB2005/003975 WO2006072831A1 (en) 2005-01-10 2005-12-28 Pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20073859L true NO20073859L (no) 2007-10-03

Family

ID=36463340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073859A NO20073859L (no) 2005-01-10 2007-07-23 Pyrrolopyrazoler, potente kinaseinhibitorer

Country Status (29)

Country Link
US (2) US8067591B2 (de)
EP (1) EP1838718B1 (de)
JP (1) JP4250195B2 (de)
KR (1) KR100919343B1 (de)
CN (1) CN101115760B (de)
AP (1) AP2007004061A0 (de)
AT (1) ATE512972T1 (de)
AU (1) AU2005323797B2 (de)
BR (1) BRPI0518509A2 (de)
CA (1) CA2593428C (de)
CU (1) CU23778B7 (de)
CY (1) CY1111752T1 (de)
DK (1) DK1838718T3 (de)
EA (1) EA011815B1 (de)
ES (1) ES2365245T3 (de)
GE (1) GEP20094785B (de)
HR (1) HRP20110485T1 (de)
IL (1) IL184275A0 (de)
MA (1) MA29141B1 (de)
MX (1) MX2007008385A (de)
NO (1) NO20073859L (de)
NZ (1) NZ556273A (de)
PL (1) PL1838718T3 (de)
PT (1) PT1838718E (de)
RS (1) RS51891B (de)
SI (1) SI1838718T1 (de)
TN (1) TNSN07254A1 (de)
WO (1) WO2006072831A1 (de)
ZA (1) ZA200705628B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568692A (en) 2005-12-21 2011-07-29 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
CN101646673B (zh) * 2007-02-07 2014-06-25 辉瑞大药厂 作为pkc抑制剂的3-氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CA2677572C (en) 2007-02-07 2012-12-18 Pfizer Inc. 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
AU2008237660B2 (en) 2007-04-12 2011-12-22 Pfizer Inc. 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
EP2145891A1 (de) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substierte 5-Carboxy-Oxadiazin-Chinolon-Derivate, ihre Herstellung und ihre Anwendung als antibakterielle Mittel
WO2011044264A2 (en) * 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
AU2013214137A1 (en) 2012-02-03 2014-08-21 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
AU2013214353A1 (en) 2012-02-03 2014-08-21 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
EP2825533B1 (de) 2012-03-13 2016-10-19 Basf Se Fungizide pyrimidin-verbindungen
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
IN2015DN02877A (de) * 2012-10-15 2015-09-11 Pfizer Ireland Pharmaceuticals
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MX394157B (es) 2015-06-15 2025-03-24 Ube Corp Derivado de dihidropirrolopirazol sustituido.
CN104926735A (zh) * 2015-06-16 2015-09-23 上海合全药物研发有限公司 4-氯-5-氟-2-甲基嘧啶的工业化制备方法
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CA3097543A1 (en) * 2018-04-16 2019-10-24 The Regents Of The University Of California Pak4 inhibitors and methods of use
EP3810132A4 (de) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Kinaseinhibitoren der taire und ihre verwendungen
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (de) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von durch nlrp3-inflammasom vermittelten il-1-beta-abhängigen erkrankungen
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
CN111454278B (zh) * 2020-05-15 2021-03-19 四川大学 Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CN121248675A (zh) * 2020-12-31 2026-01-02 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
CA2493637A1 (en) * 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
AU2005323797B2 (en) 2009-07-09
KR100919343B1 (ko) 2009-09-25
US20100222342A1 (en) 2010-09-02
PT1838718E (pt) 2011-08-17
US8530652B2 (en) 2013-09-10
PL1838718T3 (pl) 2011-10-31
US20120264751A1 (en) 2012-10-18
DK1838718T3 (da) 2011-07-25
IL184275A0 (en) 2007-10-31
CA2593428A1 (en) 2006-07-13
CU23778B7 (es) 2012-02-15
RS51891B (sr) 2012-02-29
AU2005323797A1 (en) 2006-07-13
CA2593428C (en) 2012-04-17
TNSN07254A1 (en) 2008-12-31
HK1114380A1 (en) 2008-10-31
CU20070160A7 (es) 2009-03-16
EP1838718A1 (de) 2007-10-03
EP1838718B1 (de) 2011-06-15
JP4250195B2 (ja) 2009-04-08
HRP20110485T1 (hr) 2011-07-31
CN101115760A (zh) 2008-01-30
US8067591B2 (en) 2011-11-29
KR20070096007A (ko) 2007-10-01
ES2365245T3 (es) 2011-09-27
CN101115760B (zh) 2010-11-03
EA011815B1 (ru) 2009-06-30
NZ556273A (en) 2010-01-29
ATE512972T1 (de) 2011-07-15
AP2007004061A0 (en) 2007-08-31
MX2007008385A (es) 2007-08-21
GEP20094785B (en) 2009-09-25
ZA200705628B (en) 2008-11-26
WO2006072831A1 (en) 2006-07-13
EA200701257A1 (ru) 2007-12-28
CY1111752T1 (el) 2015-10-07
JP2008526826A (ja) 2008-07-24
MA29141B1 (fr) 2008-01-02
BRPI0518509A2 (pt) 2008-11-25
SI1838718T1 (sl) 2011-08-31

Similar Documents

Publication Publication Date Title
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20090628L (no) Pyridizinon derivativater
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20081454L (no) Met-kinaseinhibitorer
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20082598L (no) ERBB-inhibitorer
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20071593L (no) Pyrimidinderivater
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20080061L (no) Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20073572L (no) Nye forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application